Wide Ranks

CING

Cingulate Inc.

4.20

Top Statistics
Market Cap 13 M Forward PE -0.9767 Revenue Growth 0.00 %
Current Ratio 7.35 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.1530 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 10 M Total Cash Per Share 5.68 Total Debt 234174
Total Debt To Equity 1.95 Current Ratio 7.35 Book Value Per Share 6.82
All Measures
Short Ratio 42.00 % Message Board Id finmb_1674914781 Shares Short Prior Month 38266
Return On Equity -2.74 City Kansas City Uuid bf898f9d-c1c1-3f31-9c96-a5b2c0f73dcd
Previous Close 4.36 First Trade Date Epoch Utc 1 B Book Value 6.82
Total Debt 234174 Volume 190582 Price To Book 0.6163
Last Split Date 1 B Fifty Two Week Low 1.80 Total Cash Per Share 5.68
Shares Short Previous Month Date 1 B Target Median Price 62.00 Max Age 86400
Recommendation Mean 1.50 Sand P52 Week Change 0.3133 Target Mean Price 48.33
Net Income To Common -16348455 Short Percent Of Float 0.0248 Implied Shares Outstanding 3 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 131560
Average Volume10days 131560 Total Cash 10 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0330 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 4.36 Target Low Price 8.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 4.49 Open 4.35
Free Cashflow -10794803 State KS Dividend Yield 0.00 %
Return On Assets -1.04 Time Zone Short Name EST Trailing Eps -43.22
Day Low 3.94 Address1 1901 West 47th Place Shares Outstanding 3 M
Price Hint 4 Target High Price 75.00 Website https://www.cingulate.com
52 Week Change -0.9442 Average Volume 306390 Forward Eps -7.31
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 651.00 %
Last Split Factor 1:12 Regular Market Day High 4.35 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 1.95 Fifty Two Week High 152.40
Day High 4.35 Shares Short 77148 Regular Market Open 4.35
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0240 Operating Cashflow -16934228 Currency USD
Time Zone Full Name America/New_York Market Cap 13 M Is_nasdaq_100 False
Zip 66205 Quote Type EQUITY Industry Biotechnology
Long Name Cingulate Inc. Regular Market Day Low 3.94 Held Percent Institutions 0.0156
Current Price 4.20 Enterprise To Ebitda 0.1530 Financial Currency USD
Current Ratio 7.35 Industry Disp Biotechnology Number Of Analyst Opinions 3
Country United States Float Shares 1 M Two Hundred Day Average 7.93
Enterprise Value -2387254 Forward PE -0.9767 Regular Market Volume 190582
Ebitda -15568522 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States.

The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.

It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety.

The company was founded in 2012 and is headquartered in Kansas City, Kansas.